Results 201 to 210 of about 468,836 (265)

Clinical pharmacology in adolescent transgender medicine. [PDF]

Br J Clin Pharmacol
Cirrincione LR, Huang KJ, Sequeira GM.
europepmc   +1 more source

Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results. [PDF]

Clin Pharmacol Ther
Gong J, Zhou J, Yuan D, Ma X, Vishwamitra D, Hilder B, Masterson TJ, Tolbert J, Renaud T, Heuck C, Kane C, Samtani MN, Girgis S, Haddish-Berhane N, Berdeja J, Krishnan A, Ouellet D.   +16 more
europepmc   +1 more source

AI-Driven Applications in Clinical Pharmacology and Translational Science: Insights From the ASCPT 2024 AI Preconference. [PDF]

Clin Transl Sci
Shahin MH, Desai P, Terranova N, Guan Y, Helikar T, Lobentanzer S, Liu Q, Lu J, Madhavan S, Mo G, Musuamba FT, Podichetty JT, Shen J, Xie L, Wiens M, Musante CJ.   +15 more
europepmc   +1 more source

Agents for Change: Artificial Intelligent Workflows for Quantitative Clinical Pharmacology and Translational Sciences. [PDF]

Clin Transl Sci
Shahin MH, Goswami S, Lobentanzer S, Corrigan BW.   +3 more
europepmc   +1 more source

Flecainide Toxicity From Clinical Pharmacology Perspectives. [PDF]

Cureus
Otani N, Wakuda H, Oikawa I, Uemura N, Yasu T.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical Pharmacology of Cilazapril

Drugs, 1989
In clinical pharmacology studies, cilazapril, after its bioactivation to cilazaprilat, was characterised as a potent, reversible angiotensin converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours, which is consistent with saturable binding to ACE.
C H, Kleinbloesem, P, Van Brummelen, R J, Francis, U W, Wiegand   +3 more
openaire   +3 more sources

Clinical Pharmacology of Inodilators

Journal of Cardiovascular Pharmacology, 1989
Recent advances in our knowledge of heart failure have shown that both a central and a peripheral factor are involved in this syndrome. Therefore, the ideal drug should combine the properties of a positive inotropic agent with those of a peripheral vasodilator; many drugs recently introduced into clinical practice have been shown to present both of ...
DEI CAS, Livio, METRA, Marco, VISIOLI, Odoardo   +2 more
openaire   +4 more sources

The chemistry, pharmacology and clinical pharmacology of diflunisal

Current Medical Research and Opinion, 1978
Studies are reviewed on diflunisal, a new analgesic agent with an improved therapeutic index, compared with acetylsalicylic acid, in animals and humans. Pharmacokinetic data indicate that a twice-daily dosage regimen of diflunisal is adequate for therapeutic purposes.
S L, Steelman, V J, Cirillo, K F, Tempero   +2 more
openaire   +2 more sources

Clinical Pharmacology

JAMA: The Journal of the American Medical Association, 1989
The issue of what drug effects to measure, surrogate end points, has been emphasized by two recent clinical trials. Several recent studies have given us new information about why different people react so differently to the same dose of the same medicine.
openaire   +5 more sources

Clinical pharmacology of progestins

Minerva Obstetrics and Gynecology, 2022
In this paper, we report general pharmacological profile and major biological activities of natural progesterone (P) and progestins. The aim of this article consists of synthesizing the principal aspects of pharmacology and metabolism of P and progestins related to the clinical consequences of their use.We review scientific literature on the topic ...
Capozzi, Anna, Scambia, Giovanni, Lello, Stefano   +2 more
openaire   +3 more sources